[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Hargadon, K.M., Johnson, C.E. and Williams, C.J. (2018) Immune Checkpoint Blockade Therapy for Cancer: An Overview of FDA-Approved Immune Checkpoint Inhibitors. International Immunopharmacology, 62, 29-39. https://doi.org/10.1016/j.intimp.2018.06.001
|
[3]
|
Dai, X., Gao, Y. and Wei, W. (2022) Post-Translational Regulations of PD-L1 and PD-1: Mechanisms and Opportunities for Combined Immunotherapy. Seminars in Cancer Biology, 85, 246-252. https://doi.org/10.1016/j.semcancer.2021.04.002
|
[4]
|
Iwai, Y., Hamanishi, J., Chamoto, K., et al. (2017) Cancer Immunotherapies Targeting the PD-1 Signaling Pathway. Journal of Biomedical Science, 24, Article No. 26. https://doi.org/10.1186/s12929-017-0329-9
|
[5]
|
Allin, K.H. and Nordestgaard, B.G. (2011) Elevated C-Reactive Protein in the Diagnosis, Prognosis, and Cause of Cancer. Critical Reviews in Clinical Laboratory Sciences, 48, 155-170. https://doi.org/10.3109/10408363.2011.599831
|
[6]
|
Cehreli, R., Yavuzsen, T., Ates, H., et al. (2019) Can Inflammatory and Nutritional Serum Markers Predict Chemotherapy Outcomes and Survival in Advanced Stage Nonsmall Cell Lung Cancer Patients? BioMed Research International, 2019, Article ID: 1648072. https://doi.org/10.1155/2019/1648072
|
[7]
|
Geng, Y., Qi, Q., Sun, M., et al. (2015) Prognostic Nutritional Index Predicts Survival and Correlates with Systemic Inflammatory Response in Advanced Pancreatic Cancer. European Journal of Surgical Oncology, 41, 1508-1514. https://doi.org/10.1016/j.ejso.2015.07.022
|
[8]
|
Riedl, JM., Posch, F., Moik, F., et al. (2017) Inflammatory Biomarkers in Metastatic Colorectal Cancer: Prognostic and Predictive Role beyond the First Line Setting. Oncotarget, 8, 96048-96061. https://doi.org/10.18632/oncotarget.21647
|
[9]
|
Lococo, F., Chiappetta, M., Evangelista, J., et al. (2022). Role of Peripheral Blood Markers for Detecting Response and Predicting Prognosis in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Therapy and Surgery. Lung, 200, 393-400. https://doi.org/10.1007/s00408-022-00541-2
|
[10]
|
Shen, L., Li, Z.M. and Lu, S. (2011) [Clinical Significa,Nce of C-Reactive Protein in Patients with Stage I Non-Small Cell Lung Cancer]. Chinese Journal of Oncology, 33, 442-446.
|
[11]
|
Gupta, D. and Lis, C.G. (2010) Pretreatment Serum Albumin as a Predictor of Cancer Survival: A Systematic Review of the Epidemiological Literature. Nutrition Journal, 9, Article No. 69. https://doi.org/10.1186/1475-2891-9-69
|
[12]
|
Guller, M., Herberg, M., Amin, N., et al. (2021) Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer. Cancers, 13, Article 5772. https://doi.org/10.3390/cancers13225772
|
[13]
|
Hurkmans, D.P., Basak, E.A., Van Dijk, T., et al. (2019) A Prospective Cohort Study on the Pharmacokinetics of Nivolumab in Metastatic Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Cancer Patients. The Journal for ImmunoTherapy of Cancer, 7, 192.
|
[14]
|
Zheng, M. (2022) Serum Albumin: A Pharmacokinetic Marker for Optimizing Treatment Outcome of Immune Checkpoint Blockade. Journal for ImmunoTherapy of Cancer, 10, e005670. https://doi.org/10.1136/jitc-2022-005670
|
[15]
|
Liu, C., Bai, Y., Liu, Y., et al. (2023) Effect of Standard Nutritional Support Therapy Based on Nutritional Risk Screening on Post-Operative Nutritional Status and Quality of Life in Patients with Glioma. American Journal of Translational Research, 15, 6217-6225.
|
[16]
|
Pu, D., Xu, Q., Zhou, LY., et al. (2021) Inflammation-Nutritional Markers of Peripheral Blood Could Predict Survival in Advanced Non-Small-Cell Lung Cancer Patients Treated with PD-1 Inhibitors. Thoracic Cancer, 12, 2914-2923. https://doi.org/10.1111/1759-7714.14152
|
[17]
|
Chen, N., Yu, Y., Shen, W., et al. (2023) Nutritional Status as Prognostic Factor of Advanced Oesophageal Cancer Patients Treated with Immune Checkpoint Inhibitors. Clinical Nutrition, 43, 142-153. https://doi.org/10.1016/j.clnu.2023.11.030
|
[18]
|
Mok, T.S.K., Wu, Y.L., Kudaba, I., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. Lancet, 393, 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7
|
[19]
|
Li, Q., Han, J., Yang, Y. and Chen, Y. (2022) PD-1/PD-L1 Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma Immunotherapy. Frontiers in Immunology, 13, Article 1070961. https://doi.org/10.3389/fimmu.2022.1070961
|
[20]
|
Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science, 359, 1350-1355. https://doi.org/10.1126/science.aar4060
|
[21]
|
Marabelle, A., Fakih, M., Lopez, J., et al. (2020). Association of Tumour Mutational Burden with Outcomes in Patients with Advanced Solid Tumours Treated with Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study. The Lancet Oncology, 21, 1353-1365. https://doi.org/10.1016/S1470-2045(20)30445-9
|
[22]
|
Le, D.T., Durham, J.N., Smith, K.N., et al. (2017) Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. Science, 357, 409-413. https://doi.org/10.1126/science.aan6733
|
[23]
|
Davis, A.A. and Patel, V.G. (2019) the Role of PD-L1 Expression as a Predictive Biomarker: An Analysis of All US Food and Drug Administration (FDA) Approvals of Immune Checkpoint Inhibitors. Journal for Immuno Therapy of Cancer, 7, 278. https://doi.org/10.1186/s40425-019-0768-9
|
[24]
|
Garassino, M.C., Gadgeel, S., Esteban, E., et al. (2020) Patient-Reported Outcomes Following Pembrolizumab or Placebo plus Pemetrexed and Platinum in Patients with Previously Untreated, Metastatic, Non-Squamous Non-Small-Cell Lung Cancer (KEYNOTE-189): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 21, 387-397. https://doi.org/10.1016/S1470-2045(19)30801-0
|
[25]
|
Shiravand, Y., Khodadadi, F., Kashani, S.M.A., et al. (2022) Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 29, 3044-3060. https://doi.org/10.3390/curroncol29050247
|
[26]
|
Nigam, M., Mishra, A.P., Deb, V.K., et al. (2023) Evaluation of the Association of Chronic Inflammation and Cancer: Insights and Implications. Biomedicine & Pharmacotherapy, 164, Article ID: 115015. https://doi.org/10.1016/j.biopha.2023.115015
|
[27]
|
Chen, J., Wei, S., Zhao, T., et al. (2022) Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, DNLR, LMR, and PAB. Disease Marker, 2022, Article ID: 7137357. https://doi.org/10.1155/2022/7137357
|
[28]
|
Xiao, X., Wang, S. and Long, G. (2019) C-Reactive Protein Is a Significant Predictor of Improved Survival in Patients with Advanced Non-Small Cell Lung Cancer. Medicine, 98, e16238. https://doi.org/10.1097/MD.0000000000016238
|
[29]
|
Zhu, M., Ma, Z., Zhang, X., et al. (2022) C-Reactive Protein and Cancer Risk: A Pan-Cancer Study of Prospective Cohort and Mendelian Randomization Analysis. BMC Medicine, 20, Article No. 301. https://doi.org/10.1186/s12916-022-02506-x
|
[30]
|
Zheng, F., Meng, Q., Zhang, L., et al. (2023) Prognostic Roles of Hematological Indicators for the Efficacy and Prognosis of Immune Checkpoint Inhibitors in Patients with Advanced Tumors: A Retrospective Cohort Study. World Journal of Surgical Oncology, 21, Article No. 198. https://doi.org/10.1186/s12957-023-03077-8
|
[31]
|
Riedl, J.M., Barth, D.A., Brueckl, W.M., et al. (2020) C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. Cancers, 12, Article 2319. https://doi.org/10.3390/cancers12082319
|
[32]
|
Iivanainen, S., Ahvonen, J., Knuuttila, A., et al. (2019) Elevated CRP Levels Indicate Poor Progression-Free and Overall Survival on Cancer Patients Treated with PD-1 Inhibitors. ESMO Open, 4, e000531. https://doi.org/10.1136/esmoopen-2019-000531
|
[33]
|
Fanali, G., Di Masi, A., Trezza, V., et al. (2012) Human Serum Albumin: From Bench to Bedside. Molecular Aspects of Medicine, 33, 209-290. https://doi.org/10.1016/j.mam.2011.12.002
|
[34]
|
Dennis, R.A., Johnson, L.E., Roberson, P.K., et al. (2008) Changes in Prealbumin, Nutrient Intake, and Systemic Inflammation in Elderly Recuperative Care Patients. Journal of the American Geriatrics Society, 56, 1270-1275. https://doi.org/10.1111/j.1532-5415.2008.01789.x
|
[35]
|
Guo, Y., Wei, L., Patel, S.H., et al. (2022) Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy but Not Chemoimmunotherapy. Clinical Lung Cancer, 23, 345-355. https://doi.org/10.1016/j.cllc.2021.12.010
|
[36]
|
Luo, H., Huang, J., Zhu, Z., et al. (2019) Prognostic Value of Pretreatment Serum Transthyretin Level in Patients with Gastrointestinal Cancers. Disease Markers, 2019, Article ID: 7142065. https://doi.org/10.1155/2019/7142065
|
[37]
|
Han, S., Huang, Y., Li, Z., et al. (2015) The Prognostic Role of Preoperative Serum Albumin Levels in Glioblastoma Patients. BMC Cancer, 15, Article No. 108. https://doi.org/10.1186/s12885-015-1125-0
|
[38]
|
Cui, X., Jia, Z., Chen, D., et al. (2020) The Prognostic Value of the C-Reactive Protein to Albumin Ratio in Cancer: An Updated Meta-Analysis. Medicine, 99, e19165. https://doi.org/10.1097/MD.0000000000019165
|
[39]
|
Flint, T.R., Janowitz, T., Connell, C.M., et al. (2016) Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-Tumor Immunity. Cell Metabolism, 24, 672-684. https://doi.org/10.1016/j.cmet.2016.10.010
|
[40]
|
Saal, J., Ellinger, J., Ritter, M., et al. (2023) Pretreatment Albumin Is a Prognostic and Predictive Biomarker for Response to Atezolizumab across Solid Tumors. Clinical & Translational Immunology, 12, e1472. https://doi.org/10.1002/cti2.1472
|
[41]
|
Li, X.Q., Zhao, Z.L., Hou, M.L., et al. (2021) [The Influence of Cachexia on the Immunotherapy Efficacy of Sintilimab for Non-Small Cell Lung Cancer]. Chinese Journal of Oncology, 43, 1292-1297.
|
[42]
|
Landre, T., Des Guetz, G., Chouahnia, K., et al. (2020) Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First-and Second-Line Settings: A Meta-Analysis. Drugs Aging, 37, 747-754. https://doi.org/10.1007/s40266-020-00788-5
|
[43]
|
Chen, L., Zhao, R., Sun, H., et al. (2022) The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated with PD-1/PD-L1 Inhibitors. Frontiers in Pharmacology, 13, Article 833584. https://doi.org/10.3389/fphar.2022.833584
|
[44]
|
Topalian, S.L., Taube, J.M. and Pardoll, D.M. (2020)Neoadjuvant Checkpoint Blockade for Cancer Immunotherapy. Science, 367, eaax0182. https://doi.org/10.1126/science.aax0182
|
[45]
|
Bodor. J., Bauman, N., et al. (2023) Real-World Progression-Free Survival (RwPFS) and the Impact of PD-L1 and Smoking in Driver-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy. Journal of Cancer Research and Clinical Oncology, 149, 1755-1763. https://doi.org/10.1007/s00432-022-04089-9
|
[46]
|
Johnson, D.B., Nebhan, C.A., Moslehi, J.J., et al. (2022) Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity. Nature Reviews Clinical Oncology, 19, 254-267. https://doi.org/10.1038/s41571-022-00600-w
|
[47]
|
Berner, F., Bomze, D., Diem, S., et al. (2019) Association of Checkpoint Inhibitor-Induced Toxic Effects with Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncology, 5, 1043-1047. https://doi.org/10.1001/jamaoncol.2019.0402
|
[48]
|
Tardy, M.P., Gastaud, L., Boscagli, A., et al. (2017) Autoimmune Hemolytic Anemia after Nivolumab Treatment in Hodgkin Lymphoma Responsive to Immunosuppressive Treatment. A Case Report. Hematological Oncology, 35, 875-877. https://doi.org/10.1002/hon.2338
|
[49]
|
Socinski, M.A., Jotte, R.M., Cappuzzo, F., et al. (2023) Association of Immune-Related Adverse Events with Efficacy of Atezolizumab in Patients with Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncology, 9, 527-535. https://doi.org/10.1001/jamaoncol.2022.7711
|
[50]
|
严颐丹, 刘利, 赵灵逸, 等. 一项单中心回顾性研究: 真实世界中PD-1抑制剂在晚期癌症患者免疫治疗中的有效性和安全性[J]. 肿瘤, 2023, 43(3): 161-170.
|